Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 – 2013

NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology

(2017) Phillip G. Febbo et al.   Journal of the National Comprehensive Cancer Network

Non–Small Cell Lung Cancer

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Inequalities in lung cancer: a world ofEGFR

(2016) Mélodie Carbonnaux et al.   EUROPEAN RESPIRATORY JOURNAL

Variations in Receipt of Curative-Intent Surgery for Early-Stage Non–Small Cell Lung Cancer (NSCLC) by State

(2016) Helmneh M. Sineshaw et al.   Journal of Thoracic Oncology

Validation of Claims Algorithms for Progression to Metastatic Cancer in Patients with Breast, Non-small Cell Lung, and Colorectal Cancer

(2016) Beth L. Nordstrom et al.   Frontiers in Oncology

Genomic alterations in lung adenocarcinoma

(2015) Siddhartha Devarakonda et al.   LANCET ONCOLOGY

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

(2014) Yuankai Shi et al.   Journal of Thoracic Oncology

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

(2014) Vanesa Gregorc et al.   LANCET ONCOLOGY

The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer

(2013) Wallace L. Akerley et al.   CURRENT MEDICAL RESEARCH AND OPINION

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

(2013) Neal I. Lindeman et al.   Journal of Thoracic Oncology

A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer

(2013) Thomas E. Stinchcombe et al.   Journal of Thoracic Oncology

Socioeconomic Inequalities in Lung Cancer Treatment: Systematic Review and Meta-Analysis

(2013) Lynne F. Forrest et al.   PLOS MEDICINE

VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

(2012) J L Kuiper et al.   BRITISH JOURNAL OF CANCER

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial

(2012) David P. Carbone et al.   Journal of Thoracic Oncology

VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

(2012) Oliver Gautschi et al.   LUNG CANCER

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

(2011) Vicki Leigh Keedy et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Race and Sex Differences in the Receipt of Timely and Appropriate Lung Cancer Treatment

(2009) Lisa R. Shugarman et al.   MEDICAL CARE

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Racial disparities in cancer therapy

(2008) Cary P. Gross et al.   CANCER